Bioclinica acquires clinical research company
"The Compass Research acquisition marks Bioclinica’s entry into the U.S. investigator site network," Bioclinica CEO, John Hubbard, told Outsourcing-Pharma.com.
Compass Research will become part of Bioclinica’s Research Network Division, which is part of the Global Clinical Research Business Segment.
"The Bioclinica Research Network has sites on three continents with plans to rapidly expand in the United States and other areas," added Hubbard.
The Orlando, Florida-based clinical research company’s position in the state – specifically its presence in the largest retirement community in the US – will provide Bioclinica with access to 179,000 elderly residents who could contribute to research, including arthritis, back, knee and hip pain, Alzheimer’s Disease, dementia, cardiovascular diseases, among others.
Compass Research has also curated a database through its physician network and affiliate practices with in-clinic recruiters, which includes nearly 80,000 potential subjects.
"This acquisition of Compass Research brings established, highly successful U.S. investigational sites into Bioclinica’s global research network," said Hubbard.
According to Bioclinica, the leadership team at Compass will play a strategic role in the company’s research network expansion.
"Compass will be joining a global research network with sites in Latin America, Europe, and Asia and will be a driving force in Bioclinica’s expansion into the United States," added Hubbard.
In addition to expanding the company’s research network, Hubbard said that the companies “see unique synergies” with its Medical Imaging, Biomarkers, eHealth Solutions, and Patient Recruitment-Retention teams.
As Outsourcing-Pharma.com previously reported, Bioclinica is actively partnering to provide innovative offering models and technologies.
Most recently, the company launched a new clinical trial management system (CTMS) for contract research organizations (CROs) and mid-market biopharma. It also announced an agreement to become ArisGlobal's preferred partner to support a "continuum of pharmacovigilance services."
"As with our other recent acquisitions, the primary goal in the near term is for a successful integration, ensuring no disruption to ongoing projects," explained Hubbard.
